- Select Medical press release ( NYSE: SEM ): Q4 GAAP EPS of $0.22 misses by $0.11 .
- Revenue of $1.58B (+1.3% Y/Y) in-line.
- Adjusted EBITDA for the Concentra segment was $62.2 million for the fourth quarter ended December 31, 2022, compared to $70.7 million for the same quarter, prior year.
- The Adjusted EBITDA margin for the Concentra segment was 15.0% for the fourth quarter ended December 31, 2022, compared to 17.2% for the same quarter, prior year.
-
Business Outlook for Revenue
-
Given the continued uncertainties surrounding the labor market, Select Medical is issuing its business outlook for revenue only for 2023. Select Medical expects revenue to be in the range of $6.5 billion to $6.7 billion for the full year of 2023.
For further details see:
Select Medical GAAP EPS of $0.22 misses by $0.11, revenue of $1.58B in-line